The largest database of trusted experimental protocols

Apc conjugated hla dr

Manufactured by BD

APC-conjugated HLA-DR is a fluorescently labeled antibody that binds to the HLA-DR surface antigen. HLA-DR is a class II major histocompatibility complex (MHC) protein expressed on the surface of antigen-presenting cells. The APC fluorescent dye is conjugated to the HLA-DR antibody, allowing for the identification and analysis of HLA-DR positive cells using flow cytometry.

Automatically generated - may contain errors

2 protocols using apc conjugated hla dr

1

Multiparametric Immunophenotyping of DCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies (mAbs) to CD86, CD1a, PD-L1 (CD274), IFN-γ (all anti-human), phycoerythrin (PE)-conjugated mAbs to CD80, CD83 and CD25, APC-conjugated HLA-DR (all anti-human), anti-human Alexa Fluor 700-CD4 were from BD Biosciences, and PE-conjugated mAb to anti-human CD40 was from Becton Dickinson. Human Foxp3-APC, anti-PD-L1 and isotype control were from eBioscience. CD14 magnetic beads, T cell isolation kit II, GM-CSF and IL-4 were from Miltenyi Biotec. Anti-β-ACTIN and anti-PGE2 antibodies were purchased from Sigma-Aldrich. Anti-SHH, anti-GLI1, anti-NUMB, anti-Ser9 phospho-GSK-3β, anti-NICD (Cleaved Notch1), anti-Ser2448 phospho mTOR, anti-Tyr458 phospho p85 and anti-Ser536 phospho NF-κB p65 were purchased from Cell Signaling Technology. Anti-COX-2 was from Calbiochem. Anti-Notch 2 intracellular domain and anti-Notch 4 -C-terminal antibodies were from Abcam. HRP conjugated anti-rabbit IgG and anti-mouse IgG was obtained from Jackson ImmunoResearch.
+ Open protocol
+ Expand
2

Multicolor flow cytometric analysis of MDSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
MDSCs were detected by using FITC-conjugated CD11b, PE-conjugated CD33, Per-CP-conjugated CD15, Per-CP-conjugated CD14, and allophycocyanin (APC)-conjugated HLA-DR (BD Biosciences). A blood sample (50 µL) was incubated with 5 µL each of CD33, CD11b, HLA-DR, and CD14 in one tube, and CD33, CD11b, HLA-DR, and CD15 in another tube for 20 minutes at 4 °C in the dark. Following incubation, red blood cell lysis and washing with PBS were performed. Then cells were suspended in PBS and analyzed using Cell Quest software on a FACSCalibur flow cytometer, as presented in Figure 2. An isotype-matched negative control was used for each sample. HLA-DR-negative cells were selected from the HLA-DR and side scatter histogram. The HLA-DR-negative cells were assessed for their expression of CD33 and CD11b to detect MDSCs (HLA-DR-CD33+CD11b+). Then, the MDSCs were assessed for their expression of CD15 and CD14 to detect PMN-MDSCs (HLA-DR-CD33+CD11b+CD15+) and MO-MDSCs (HLA-DR-CD33+CD11b+CD14+).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!